KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables (2017 - 2025)

Historic Receivables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $14.1 million.

  • Aquestive Therapeutics' Receivables rose 2092.29% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 2092.29%. This contributed to the annual value of $9.8 million for FY2024, which is 1378.01% down from last year.
  • Aquestive Therapeutics' Receivables amounted to $14.1 million in Q3 2025, which was up 2092.29% from $14.1 million recorded in Q2 2025.
  • Aquestive Therapeutics' Receivables' 5-year high stood at $22.6 million during Q2 2022, with a 5-year trough of $6.8 million in Q4 2022.
  • Over the past 5 years, Aquestive Therapeutics' median Receivables value was $12.7 million (recorded in 2025), while the average stood at $13.2 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Receivables tumbled by 6223.51% in 2022, and later surged by 8358.99% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Receivables (Quarter) stood at $18.1 million in 2021, then crashed by 62.24% to $6.8 million in 2022, then skyrocketed by 66.39% to $11.4 million in 2023, then fell by 13.78% to $9.8 million in 2024, then surged by 43.88% to $14.1 million in 2025.
  • Its last three reported values are $14.1 million in Q3 2025, $14.1 million for Q2 2025, and $12.7 million during Q1 2025.